AX-2025-019822 · KPV · Homopeptide lot HOMO-2411-P5026

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.75	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.25	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — diketopiperazine (−18 Da)	0.15	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	84.69	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	84.48	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	10.50	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	8.870	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	88.7	%	90.0 – 110.0	FAIL
Water content	Karl Fischer, coulometric, duplicate	4.85	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	9.85	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.61	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.14	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.01	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	5.35	min	5.24 ± 0.20 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.91	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	71,487	—	≥ 20,000	PASS
Resolution to nearest impurity	vs diketopiperazine (−18 Da)	1.83	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 71,487, and skew follows the reported asymmetry factor of 0.91. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.15 % impurity against a 99.75 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	KPV — main peak	5.35	4,848,159	99.75	—
2	diketopiperazine (−18 Da)	5.50	7,290	0.15	-18.011
3	acetyl-KPV (+42 Da)	5.65	2,916	0.06	+42.011
4	Pro-Val dipeptide (−128 Da)	4.91	1,458	0.03	-128.095
5	Lys-Pro dipeptide (−99 Da)	4.99	486	0.01	-99.068
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.85
Counter-ion (acetate)	ion chromatography	9.85
Residual solvent + inorganic residue	estimated	0.61
Total peptide content	by difference	84.69
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.56	99.75	divergence +0.08 pp vs batch median
Total impurities (% area)	0.44	0.25
Largest single impurity (% area)	not stated	0.15
Water (%)	3.7	4.85
Counter-ion (%)	6.4	9.85
Peptide content (%w/w)	89.3	84.69
Endotoxin (EU/mg)	not stated	0.14
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 17 d since original receipt) → re-assay.
Assay date: 12 Mar 2025
Submitted to the index: 03 Apr 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

median_not_mean03 Apr 2025

One result at the top of the distribution should not move anybody's estimate much on its own. Purity distributions are compressed at the top and long-tailed at the bottom, so the informative observations are the low ones.

counterion_mol03 Apr 2025

The stoichiometric prediction and the measured figure agree closely enough on this record that no excess reagent need be postulated. That is a quiet, useful result.

thin_coverage03 Apr 2025

The status field reads PURITY ONLY, which is precisely what the record is. Nothing is being withheld and nothing is being implied.

Section 7

Related records

Same batch — lot HOMO-2411-P5026 n=13

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019819	HOMO-2411-P5026	PeptideMeter	2025-Q1	99.35	4.77	91.6	Buyer-sourced	0	FAIL
AX-2025-019820	HOMO-2411-P5026	VendorInvestigate	2025-Q1	99.60	5.06	104.9	Buyer-sourced	0	PASS
AX-2025-019821	HOMO-2411-P5026	Janoshik	2025-Q1	99.48	4.62	88.6	Buyer-sourced	1	FAIL
AX-2025-019823	HOMO-2411-P5026	Medutest	2025-Q1	98.75	5.08	99.8	Buyer-sourced	0	FAIL
AX-2025-019824	HOMO-2411-P5026	Janoshik	2025-Q1	99.65	5.11	105.0	Buyer-sourced	0	PASS
AX-2025-019825	HOMO-2411-P5026	PeptideMeter	2025-Q1	99.18	4.68	—	Laboratory-retained	0	FAIL
AX-2025-019826	HOMO-2411-P5026	Janoshik	2025-Q1	99.64	4.71	106.5	Buyer-sourced	0	FAIL
AX-2025-019827	HOMO-2411-P5026	Janoshik	2025-Q1	99.80	5.64	—	Buyer-sourced	0	PASS
AX-2025-019828	HOMO-2411-P5026	VendorInvestigate	2025-Q1	99.17	4.84	105.2	Buyer-sourced	0	FAIL
AX-2025-019829	HOMO-2411-P5026	Janoshik	2025-Q1	99.07	5.03	—	Buyer-sourced	0	FAIL
AX-2025-019830	HOMO-2411-P5026	PeptideMeter	2025-Q1	98.93	4.83	93.5	Buyer-sourced	1	FAIL
AX-2025-019831	HOMO-2411-P5026	PeptideMeter	2025-Q1	99.50	4.99	—	Buyer-sourced	0	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent KPV records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042742	GGPeps	GGPE-2511-K1569	Janoshik	2026-Q2	98.40	5.09	—	Buyer-sourced	0	FAIL
AX-2026-042259	TFC	TFC-2508-M9624	Janoshik	2026-Q1	99.93	3.38	89.4	Buyer-sourced	1	FAIL
AX-2026-042078	HYB	HYB-2511-P7317	Nordanalyt	2026-Q1	99.59	3.92	98.8	Buyer-sourced	0	PASS
AX-2026-042262	TFC	TFC-2508-M9624	Janoshik	2026-Q1	99.89	3.32	92.2	Buyer-sourced	0	FAIL
AX-2026-042260	TFC	TFC-2508-M9624	PeptideMeter	2026-Q1	99.93	2.89	99.2	Buyer-sourced	0	FAIL
AX-2026-042079	HYB	HYB-2511-P7317	Janoshik	2026-Q1	99.68	5.67	94.7	Buyer-sourced	0	FAIL
AX-2026-042257	TFC	TFC-2508-M9624	Janoshik	2026-Q1	99.54	2.81	95.6	Buyer-sourced	0	FAIL
AX-2026-042261	TFC	TFC-2508-M9624	Medutest	2026-Q1	99.93	3.20	97.1	Buyer-sourced	0	FAIL

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Retatrutide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-042424	Semaglutide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	PASS
AX-2026-042503	IGF-1 LR3	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	PASS
AX-2026-042492	SS-31 (Elamipretide)	HOMO-2604-D5484	Medutest	2026-Q3	99.93	2.40	—	Buyer-sourced	PASS
AX-2026-042491	SS-31 (Elamipretide)	HOMO-2604-D5484	Kestrel	2026-Q3	99.93	3.24	—	Supplier-supplied	PASS
AX-2026-042473	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	PASS
AX-2026-042441	Retatrutide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-042474	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	PASS